Zydus Cadila receives USFDA okay for Linagliptin Tablets
Ahmedabad: Drugmaker, Zydus Cadila, has recently announced that the company has received tentative approval from the US Food & Drug Administration (USFDA) to market Linagliptin Tablets, 5 mg (US RLD: Tradjenta Tablets). Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2...
Ahmedabad: Drugmaker, Zydus Cadila, has recently announced that the company has received tentative approval from the US Food & Drug Administration (USFDA) to market Linagliptin Tablets, 5 mg (US RLD: Tradjenta Tablets).
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus.
The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.
The group now has 310 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.
Read also: Zydus Cadila gets USFDA nod for diabetes drug Dapagliflozin
The company discovers, develops, manufactures, and markets a broad range of healthcare therapies.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd